Least squares mean change from baseline at 12 and 52 weeks for PRO
| PRO measures (95% CI) | Week 12 | Week 52 | |||
| Placebo (n=488) | Baricitinib (n=487) | Adalimumab (n=330) | Baricitinib (n=487) | Adalimumab (n=330) | |
| Physical function (HAQ-DI) | −0.34 (−0.39, –0.29) | −0.66*** †† (−0.71, –0.61) | −0.56*** (−0.62, –0.50) | −0.77†† (−0.83, –0.71) | −0.66 (−0.73, –0.59) |
| Patient’s Global Assessment of Disease Activity (PtGA) | −16.7 (−18.9, –14.6) | −31.2*** †† (−33.3, –29.1) | −26.6*** (−29.1, –24.1) | −36.3††† (−38.7, –33.9) | −30.3 (−33.1, –27.5) |
| Patient’s Assessment of Pain | −17.1 (−19.4, –14.9) | −31.5*** †† (−33.7, –29.3) | −26.4*** (−29.0, –23.7) | −36.1††† (−38.6, –33.7) | −30.3 (−33.1, –27.5) |
| EuroQol-5-Dimensions (EQ-5D) | |||||
| Health State Index Score, UK algorithm | 0.102 (0.084, 0.119) | 0.184*** (0.167, 0.202) | 0.167*** (0.146, 0.188) | 0.217† (0.197, 0.238) | 0.182 (0.158, 0.206) |
| Health State Index Score, US algorithm | 0.071 (0.058, 0.083) | 0.130*** (0.118, 0.142) | 0.117*** (0.102, 0.131) | 0.154† (0.139, 0.169) | 0.129 (0.112, 0.146) |
| VAS | 7.7 (5.6, 9.8) | 14.8*** †† (12.8, 16.9) | 10.1 (7.7, 12.6) | 19.1††† (16.6, 21.5) | 11.6 (8.8, 14.5) |
*p≤0.05, **p≤0.01,***p≤0.001 versus placebo.
†p≤0.05, ††p≤0.01, †††p≤0.001 versus adalimumab.
HAQ-DI, Health Assessment Questionnaire-Disability Index; PRO, patient-reported outcomes; VAS, visual analogue scale.